Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

2014109 citationsJournal Articlehybrid Open Access

Authors

Bevacizumab has promising tolerability. Longer follow-up is needed to identify an effect on the primary endpoint of overall survival at 5 years.

Good health and well-being

Published in: The Lancet Oncology

Volume 15, Issue 6, pp. 620-630

Field-Weighted Citation Impact: 7.16